Enrolling in Medicare Advantage for 2026? Make Sure to Avoid These Big Mistakes.

With about a week left in Medicare's fall open enrollment, beneficiaries considering a 2026 switch to Medicare Advantage should evaluate provider networks, supplemental benefits, total expected out-of-pocket costs (not just premiums), and annual Medicare star ratings. The article underscores that Advantage plans offer annual out-of-pocket caps and extra services but vary widely in network access, benefit usefulness and cost structure, so careful plan selection is key to avoiding unexpected expenses or loss of preferred providers.

Analysis

Market structure: Accelerating Medicare Advantage (MA) enrollment cements pricing power for large managed-care players (UnitedHealth UNH, Humana HUM, Elevance ELV, CVS Aetna CVS) by converting unpredictable catastrophic spend into capped OOP contracts; expect margin expansion pressure on fee-for-service hospitals (HCA, Tenet THC) and Medigap writers as MA share rises ~+2–4% annually over the next 3 years. Supplemental-benefit complexity (dental/vision/hearing/meal/fitness) favors vertically integrated insurers and digital brokers that can deliver services cheaply, shifting share to scale players and third-party vendors that can lower per-member-per-month (PMPM) cost by low single-digit dollars.

Risk assessment: Primary tail risks are regulatory reversals—CMS payment-rate cuts >1–3% or tightened risk-adjustment audits/clawbacks—which could wipe 3–8% off near-term EPS for MA-heavy insurers. Near term (days–weeks) market moves will be driven by enrollment-flow headlines (open enrollment close, early sign-ups); short term (0–6 months) by CMS 2026 payment finalize and yearly star-rating updates; long-term (1–3 years) by structural MA penetration and provider contracting dynamics. Hidden dependencies include provider network adequacy and coding intensity trends; a 1–2 star downgrade or coding audit could erase premium valuation multiples quickly.

Trade implications: Favor selective long exposure to large diversified MA operators: UNH/HUM/ELV capture upside from scale, predictable PMPM economics and ancillary-service control; overweight managed-care, underweight hospital operators and standalone specialty service providers exposed to fee-for-service declines. Use options to express view (buy-call spreads on UNH/HUM to limit capital) and implement pair trades (long UNH vs short HCA) to capture relative margin compression in hospitals as MA share grows.

Contrarian angles: Consensus assumes continuous benign regulation; markets underprice the probability of CMS tightening (histor precedent 2014–2016 clawbacks and 2019 coding scrutiny). If MA enrollment growth tails off (<+1 percentage point yoy) or CMS signals benefit-restriction, short-term dislocation could create entry points in insurers — conversely, sustained MA share gains in rural areas would be underappreciated and favor telehealth/virtual-care names (e.g., TDOC) for 12–24 month asymmetric upside.

Key Decisions for Investors

• Establish a 2–3% long position in UnitedHealth Group (UNH) with a 6–12 month horizon; hedge directional risk by buying a 6-month call spread (near‑ATM to ~+10–15% strikes) to cap cost while capturing upside from continued MA enrollment and ancillary revenue.
• Allocate 1.5–2% long to Humana (HUM) for 6–12 months; prefer buying a 9–12 month call to participate in EPS re-rating if CMS maintains payment stability and star‑rating bonuses persist.
• Implement a relative-value pair: long UNH (2%) vs short HCA Healthcare (HCA) (1–1.5%) for 6–12 months to exploit margin pressure on hospitals as MA share expands; protect the short with a 6–9 month ~10% OTM put on HCA sized to limit tail risk.
• Pre-specified risk triggers: if CMS publishes a proposed MA payment cut >1.5% or if UNH/HUM lose ≥1 star in the next ratings cycle, reduce insurer longs by 50% within 5 trading days and rotate 50% of proceeds into defensive healthcare names (large pharma, biotech staples) or long telehealth exposure (TDOC 1%) for 12–24 months.
• Monitor these catalysts over the next 90 days and act: (a) final CMS 2026 payment rule (spring), (b) Jan–Feb 2026 enrollment release; if MA share growth <+1 ppt yoy on release, initiate 1–2% short positions in select MA-dependent brokers/aggregators (e.g., EHTH) as demand surprise will pressure their revenue guidance.